Myo-inositol supplementation improves cardiometabolic factors, anthropometric measures, and liver function in obese patients with non-alcoholic fatty liver disease

Arefhosseini, Sara; Roshanravan, Neda; Tutunchi, Helda; Rostami, Somayyeh; Khoshbaten, Manuchehr; Ebrahimi-Mameghani, Mehrangiz

doi:10.3389/fnut.2023.1092544

Cited by 12 publications

(10 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 5 demonstrates changes in serum liver enzymes. As we reported in our previously published paper (Arefhosseini et al., 2023 ), serum levels of ALT and AST decreased significantly in both groups. At the end of the study, MI supplementation for 8 weeks only showed improvements in the AST/ALT ratio but not in serum AST, after adjusting for the confounders.…”

Section: Resultssupporting

confidence: 87%

“…Table 5 demonstrates changes in serum liver enzymes. As we reported in our previously published paper (Arefhosseini et al, 2023), serum levels of ALT and AST decreased significantly in both groups.…”

Section: Liver Enzymessupporting

confidence: 88%

“…Zhu et al (Zhou et al, 2008) also showed that pinitol supplementation suppressed increased ALT and AST in rats fed a high-fat diet with liver damage. We also reported significant improvement in not only IR and lipid profiles but also liver function in patients with NAFLD (Arefhosseini et al, 2023) OS biomarkers, and hormonal states (Chatree et al, 2020;Croze & Soulage, 2013;Tabrizi et al, 2018). Therefore, MI appears to be a powerful element in NAFLD management.…”

Section: Discussionmentioning

confidence: 56%

“… Note : This table has been previously published (Arefhosseini et al., 2023 ). Abbreviations: BMI, Body mass index; MI, Myo‐inositol.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Does myo‐inositol supplementation influence oxidative stress biomarkers in patients with non‐alcoholic fatty liver disease?

Rostami,

Arefhosseini,

Tutunchi

et al. 2023

Food Science & Nutrition

Self Cite

View full text Add to dashboard Cite

Myo‐inositol (MI) is a carbocyclic sugar polyalcohol. MI has known to exert anti‐inflammatory, anti‐oxidant, and anti‐diabetic activities. This study aimed to investigate the effects of MI supplementation on oxidative stress biomarkers in obese patients with non‐alcoholic fatty liver disease (NAFLD). In this double‐blinded placebo‐controlled randomized clinical trial, 51 newly diagnosed obese patients with NAFLD were randomly assigned to receive either MI (4 g/day) or placebo supplements accompanied by dietary recommendations for 8 weeks. Oxidative stress biomarkers, nutritional status, as well as liver enzymes and obesity indices were assessed pre‐ and post‐intervention. A total of 48 patients completed the trial. Although anthropometric measures and obesity indices decreased significantly in both groups, the between‐group differences adjusted for confounders were non‐significant for these parameters, except for weight (p = .049); greater decrease was observed in the MI group. Iron and zinc intakes decreased significantly in both groups; however, between‐group differences were non‐significant at the end of the study. No significant between‐group differences were revealed for other antioxidant micronutrients at the study endpoint. Sense of hunger, feeling to eat, desire to eat sweet and fatty foods reduced significantly in both groups (p < .05), while the feeling of satiety increased significantly in the placebo group (p = .002). No significant between‐group differences were observed for these parameters, except for desire to eat fatty foods; a greater decrease was observed in the MI group (p = .034). Serum levels of glutathione peroxidase (GPx) and superoxide dismutase (SOD) significantly increased in both study groups (p < .05); however, the between‐group differences were non‐significant at the end of the study. Furthermore, the between‐group differences were non‐significant for other oxidative stress biomarkers, except for serum nitric oxide (NO) level; a greater decrease was observed in the MI group. MI supplementation could significantly improve weight, desire to eat fatty foods, serum levels of NO, as well as the aspartate aminotransferase (AST)/ALT ratio.

show abstract

Section: Resultssupporting

confidence: 87%

Section: Liver Enzymessupporting

confidence: 88%

Section: Discussionmentioning

confidence: 56%

“… Note : This table has been previously published (Arefhosseini et al., 2023 ). Abbreviations: BMI, Body mass index; MI, Myo‐inositol.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Does myo‐inositol supplementation influence oxidative stress biomarkers in patients with non‐alcoholic fatty liver disease?

Rostami,

Arefhosseini,

Tutunchi

et al. 2023

Food Science & Nutrition

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is a growing health concern globally and has been associated with modern lifestyle habits such as a sedentary lifestyle, unhealthy diet, and excessive alcohol consumption [16]. The primary cause of fatty liver is the accumulation of fat in the liver cells.…”

Section: Introductionmentioning

confidence: 99%

Enhanced Non-Alcoholic Fatty Liver Detection: CT Scan Image Analysis and Noise Reduction with Morphological Dilation

Pithani,

Vadhi

2023

Preprint

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a liver disease characterized by an accumulation of fat in the liver cells, not caused by alcohol consumption. It is the most common chronic liver disease worldwide and can lead to more severe con- ditions, such as cirrhosis and liver cancer. NAFLD is often associated with other metabolic disorders, such as obesity and diabetes, and is closely related to lifestyle factors such as diet and physical activity [1]. The diagnosis and management of NAFLD are complex and involve a multidisciplinary approach. Treatment options include lifestyle modifications, pharmacological interventions, and in severe cases, liver transplantation. The increasing prevalence of NAFLD highlights the urgent need for effective prevention and management strategies. It is a growing health concern in India, given the rise in the incidence of obe- sity and diabetes. According to a study published in the Journal of Clinical and Experimental Hepatology in 2020, the prevalence of NAFLD in India is estimated to be between 9% and 32%. In accordance with the research population and diagnostic criteria employed, a different study that was published in the Indian Journal of Gastroenterology in 2019 found that the prevalence of NAFLD in India ranges from 9.6–32.3% [2]. The same study also found that the prevalence of non-alcoholic steatohepatitis (NASH), a more severe form of NAFLD, ranged from 1.5–8.4%. These statistics highlight the need for increased awareness and preventive measures to tackle the growing burden of NAFLD in India.

show abstract

The effect of myo‐inositol supplementation on AMPK/PI3K/AKT pathway and insulin resistance in patients with NAFLD

Aghajani,

Arefhosseini,

Ebrahimi‐Mameghani

et al. 2024

Food Science & Nutrition

View full text Add to dashboard Cite

Insulin resistance (IR) is the pivotal pathological hit in non‐alcoholic fatty liver disease (NAFLD). There is specific attention to combination/conjugated therapies for NAFLD management. As myo‐inositol (MI) has been shown to improve IR in animal and human trials, this study aimed to investigate the influence of MI supplementation on glycemic response and IR through AMPK/PI3K/AKT signaling pathway in obese patients with NAFLD. This double‐blinded placebo‐controlled randomized clinical trial was conducted on 48 obese (BMI = 30–40 kg/m2) patients with NAFLD who were randomly assigned to receiving either MI (4 g/day) or placebo (maltodextrin 4 g/day) group for 8 weeks. Before and after the trial, weight, height, serum glycemic parameters (inc. fasting glucose and insulin) as well as IR indices were assessed. Moreover, the mRNA expression levels of AMPK, AKT, and PDK‐1 in peripheral blood mononuclear cells (PBMCs) were determined. MI supplementation resulted in significant increases in the fold changes of AMPK, AKT, and PDK‐1 genes (p = .019, p = .049, and p = .029, respectively). Indeed, IR improved in terms of all IR indices in MI group (p < .05) after adjusting for the confounders, apart from quantitative insulin sensitivity check index (QUICKI). The results showed that MI supplementation not only upregulated AMPK, AKT, and PDK‐1 mRNA in PBMCs but also improved IR in obese patients with NAFLD.

show abstract

Myo-inositol supplementation improves cardiometabolic factors, anthropometric measures, and liver function in obese patients with non-alcoholic fatty liver disease

Cited by 12 publications

References 48 publications

Does myo‐inositol supplementation influence oxidative stress biomarkers in patients with non‐alcoholic fatty liver disease?

Does myo‐inositol supplementation influence oxidative stress biomarkers in patients with non‐alcoholic fatty liver disease?

Enhanced Non-Alcoholic Fatty Liver Detection: CT Scan Image Analysis and Noise Reduction with Morphological Dilation

The effect of myo‐inositol supplementation on AMPK/PI3K/AKT pathway and insulin resistance in patients with NAFLD

Contact Info

Product

Resources

About